Lv4
760 积分 2021-06-29 加入
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
4天前
已完结
Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review
4天前
已完结
抗体偶联药物在EGFR-TKI耐药后的NSCLC诊疗研究进展
5天前
已完结
Dual PD-1 and VEGF blockade in oncogene-negative NSCLC: where do we stand?
9天前
已关闭
Emerging landscape of KRAS inhibitors in cancer treatment
16天前
已完结
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
18天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
18天前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
19天前
已完结
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
19天前
已完结
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
19天前
已完结
皖公网安备34019202002308